The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review

Abstract

BackgroundThe genetic alterations of papillary thyroid carcinoma (PTC) have been reported to change over the past few decades. We performed this systematic review to further examine the trends and modifications of patient demographic, clinicopathological features and molecular profiles of PTC over time.MethodsA literature search was performed within six electronic databases to identify relevant articles. The inclusion criteria were published studies investigating BRAF mutations, RET/PTC rearrangements or RAS mutations in PTCs or classical PTCs. Two teams of reviewers independently screened titles and abstracts of all articles. Full texts of potential articles were read and extracted data were listed and stratified into an excel file according to country, city, institution, and surgical time period. Student t test and Pearson Chi-square were used to analyze the trends of demographic and clinicopathological features of PTC patients and the prevalence of each genetic alteration in individual institutions.ResultsFrom 3139 articles, we included 16 articles for final analysis. Our results showed an increasing trend of BRAF and a decreasing trend of RET/PTC prevalence over time in PTCs and classical PTCs, accompanied by an older age of PTC patients, an increase in proportion of PTMC and less aggressive behaviours of tumours.ConclusionsThe demographic and clinicopathological characteristics and molecular profile of PTCs have been changing over the past few decades. These modifications suggest changes in etiologies and risk factors of thyroid cancer that influence the tumorigenesis of PTCs.

Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience

“…Elisei et al (30) suggested that iodine supplementation might be associated with the increasing trend of BRAF mutation in PC. The frequency of BRAF mutations reported in the literature has increased significantly over the years (31). This may be related to innovations in methodologies used to detect mutations.…”

“…In general, the detection sensitivity of NGS reported in previous studies is >94% (40), which is greater than that of SGS. Results from numerous studies and meta-analyses have associated the BRAF V600E mutation with high-risk clinicopathologic features, such as larger tumor size, extrathyroidal extension, higher stage at presentation, and lymph node and distant metastases in patients with PC (4,20,22,30,31,(41)(42)(43). However, these associations remain controversial.…”

Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers

“…The incidence of thyroid cancers is rapidly increasing [1] with a projected prevalence of about 5539 cases in the year 2017. The major histological types of thyroid cancers are papillary, follicular, medullary and anaplastic thyroid cancers.…”

Long non‐coding PANDAR as a novel biomarker in human cancer: A systematic review

“…62 It was reported that TC was steadily increasing in morbidity and mortality over the years. According to epidemiological data, the incidence of TC has been increased by an average of 4.5% per year from 2007 to 2011 in the United States.…”